Arya Marganda Simanjuntak

Arya Marganda Simanjuntak

Auto-generated profile, based on publicly available information

Arya Marganda Simanjuntak

Faculty of Medicine, Universitas Riau, Pekanbaru

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2023 in Narra J
Verified
Journal Article
Open access
PDF file
ASArya M. Simanjuntak
Arya M. Simanjuntak
RDRaehan Satya Deanasa
Raehan Satya Deanasa
PAPutri M. Afladhanti
Putri M. Afladhanti
IYIndra Yovi
Indra Yovi
SSSuyanto Suyanto
Suyanto Suyanto
DRDani Rosdiana
Dani Rosdiana
Concerns regarding the rise of drug-resistant tuberculosis (DR-TB) infections and the need for new drugs with shorter treatment time and fewer side effects have been voiced by the World Health Organization (WHO). The WHO revised its guideline to treat multi-drug resistant tuberculosis (MDR-TB) with a 6-month course of BPaLM (bedaquiline, pretomanid, linezolid and moxifloxacin) in 2022. However, a thorough study and meta-analysis of available evidence is required due to the limited confidence of the evidence confirming the effectiveness of pretomanid-containing regiments. The aim of this systematic review and meta-analysis was to evaluate the effectiveness of pretomanid-containing regiments in treating DR-TB patients. Data from six search engines were searched using inclusion criteria based on the PICOS framework. The keywords of pretomanid and tuberculosis or their alternatives were used. Using RoB2 Cochrane risk-of-bias tool for randomized clinical trials, data were independently extracted and the quality of the data was evaluated. Odds ratio (OR) and heterogeneity tests were used and the findings were presented in ORs and forest plots. A total of four studies with 237 patients was included in the final analysis and 204 (86%) patients had favorable outcome (cured) and 33 (14%) was not cured. Pretomanid-containing regimen (OR: 46.73; 95%CI: 11.76–185.7) and BPaLM/BPaL (OR: 41.67; 95%CI: 8.86–196.73) regimens were associated with favorable outcome (cured). This meta-analysis indicates that the pretomanid-containing regimen and the BPaLM/BPaL regimen could increase the chance to have favorable outcome in DR-TB patients.

31 May 2023 in Jurnal Respirasi
Verified
Journal Article
Open access
PDF file
ASArya Marganda Simanjuntak
Arya Marganda Simanjuntak
AHAnastasya Hutapea
Anastasya Hutapea
BTBryan Steffanus Tampubolon
Bryan Steffanus Tampubolon
SBStephani Browlim
Stephani Browlim
YNYosep Pebriyanto Napitupulu
Yosep Pebriyanto Napitupulu
SSSuyanto Suyanto
Suyanto Suyanto
Vape fans claim that vaping is the solution of smoking cessation, but this is still debatable. Even if vape is still considered new, numerous studies show vaping is associated with lung injury (EVALI). Despite this, the trend of vaping is still increasing. This study aims to review current understanding of conventional smoking and vaping and comparing both. Is vaping safer than smoking? Smoking has health risk for lung cancer, COPD, stroke, and others meanwhile vaping has been linked with lung injury (EVALI). Local perfusions were decreased in tobacco smokers after exposure. However, perfusion increased in vaping after exposure. Bronchoalveolar lavage in vape users showed increase of vitamin E acetate possibly causing impairment in lung structure and functionality of surfactant. This is the potential mechanism of EVALI in vape users. Smoking uses the Brinkman Index to determine severity of smoking but there’s no index for vaping because it depends not on how many sticks but how many e-liquids were used. It seems that vape is “safer” rather than smoking but between smoking and vaping both have their own risk in health aspects and it’s safe to assume that neither is safe for use. “Vape is the solution for smoking cessation” needs further research because researchers need years to understand conventional smoking in relation with other diseases. Prospective follow-up studies to determine the risk of vaping on other diseases are needed in the future.

8 September 2025 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
DRDani Rosdiana
Dani Rosdiana
ASArya Marganda Simanjuntak
Arya Marganda Simanjuntak
NENabila Cindi Ediwi
Nabila Cindi Ediwi
RPRahmi Triana Putri
Rahmi Triana Putri
ZNZuyyina E.R. Nurrahma
Zuyyina E.R. Nurrahma
AEAisyah Elliyanti
Aisyah Elliyanti
Background: Streptococcus pneumoniae is a leading cause of respiratory infections and invasive disease. Although its burden in children is well-known, adult asymptomatic carriage remains under-investigated, particularly in tropical regions. Methods: This meta-analysis, registered in PROSPERO (CRD420244559641) and adhering to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines, searched PubMed, ScienceDirect, and Epistemonikos for studies published in the past decade. Eligible studies on adult carriage were included in the PECOS framework. Data were independently extracted by multiple reviewers and pooled using a random-effects meta-analysis. Subgroup analyses evaluated differences by sex, comorbidities [e.g., human immunodeficiency virus (HIV), diabetes], and behavioral factors (e.g., contact with children). Geospatial variations were mapped using RStudio and ggplot2, and study quality was appraised via the Joanna Briggs Institute tools. Results: Thirty-two studies (n = 56,409) revealed a pooled carriage prevalence of 17% (95% CI: 0.12–0.23). Carriage was higher in females (57% vs. 47% in males) and in HIV-positive individuals (78%), while type 2 diabetes was linked to lower carriage (6%). Elevated rates were mapped in Gambia, Fiji, and Malawi. Non-vaccine serotypes (68%) predominated over vaccine serotypes (32%). Discussion: Adult S. pneumoniae carriage is globally significant and heterogeneous, underscoring the need for targeted surveillance and vaccination strategies, especially in tropical, high-density settings.

1 September 2023 in Siriraj Medical Journal
Verified
Journal Article
Open access
PDF file
ASArya Marganda Simanjuntak
Arya Marganda Simanjuntak
RARahmadini Aulia
Rahmadini Aulia
DBDhewa Triguna Banjarnahor
Dhewa Triguna Banjarnahor
RHRiski Dimas Harianja
Riski Dimas Harianja
IYIndra Yovi
Indra Yovi
Objective: Bedaquiline is recommended by World Health Organization (WHO) to treat Drug-Resistant Tuberculosis (DR-TB). Bedaquiline is chosen due to its efficacy and safety in numerous studies. One adverse event that could happen is QT interval prolongation, which increases the risk of Torsade de Pointes (TdP) and leads to death. This study aimed to discuss the knowledge on the effect of bedaquiline on before-after and changes of QT interval. Materials and Methods: This systematic review based on PRISMA guidelines through PubMed, Cochrane, Science Direct, ProQuest, Google Scholar, and Epistemonikos until April 10, 2023. The keywords used was (“Bedaquiline” AND “QT Interval”). We implemented inclusion and exclusion criteria by PICOS framework then assessed the studies by Joanna Briggs Institute (JBI) critical appraisal checklist tools. Results: From 1.170 articles, eleven articles met the criteria. In total 2449 patients assessed in this study. Most of the studies carried out treatment duration of 6 months. There was a change in the mean QT interval between 11ms to 52.5ms in patients using bedaquiline from the beginning to the end of treatment. The mean QT interval after treatment ranges from 409.7ms – 464.5ms. Conclusion: The use of bedaquiline requires attention to the ECG before and during therapy. Regular monitoring is necessary to prevent QT prolongation.

29 August 2025 in F1000Research
Verified
Journal Article
Open access
PDF file
KMKrisna Murti
Krisna Murti
ZAZulkhair Ali
Zulkhair Ali
SBSyahri Banun
Syahri Banun
ASArya Marganda Simanjuntak
Arya Marganda Simanjuntak
PAPutri Mahirah Afladhanti
Putri Mahirah Afladhanti
RDRaehan Satya Deanasa
Raehan Satya Deanasa
* Introduction Sepsis, a dysregulated immune response to infection, is a leading cause of in-hospital mortality. While intravenous fluid resuscitation is the cornerstone of early therapy, the optimal volume and strategy are debated. This systematic review and meta-analysis aimed to synthesize the latest evidence comparing the efficacy and safety of restrictive versus liberal fluid resuscitation in adult sepsis patients. Methods Following the PRISMA Guideline 2020 (PROSPERO: CRD420251081057), a systematic review and meta-analysis of RCTs/CTs published between 2015-2024 was conducted. Databases, including PubMed, ScienceDirect, Epistemonikos, and Google Scholar, were searched using keywords such as “sepsis” AND “fluid restriction” AND “mortality.” Data extraction and risk of bias (RoB2) analysis were performed independently. Meta-analysis was performed using RevMan 5.4 with a random effects model for mortality and vasopressor-free days. Result Fourteen articles (4097 patients) were included. Mortality analyses at 7, 28, 30, and 90 days showed no statistically significant differences between restrictive and control fluid strategies, despite some individual trends. There was no discernible effect on the days alive without vasopressors (MD 0.53 days, I2 = 62%). The risk of bias varied, with five low-, seven medium-, and three high-risk studies. Publication bias suggests the possibility of small, unpublished studies. Conclusion This meta-analysis found no significant mortality difference between restrictive and liberal fluid resuscitation in adults with sepsis, nor a significant impact on vasopressor-free days. Restrictive strategies do not increase harm and may reduce complications such as mechanical ventilation. Future research needs consistent fluid definitions and patient stratification according to severity [e.g., Sequential Organ Failure Assessment Score (SOFA) scores] to clarify optimal fluid management in sepsis.

27 January 2024 in Journal Of The Indonesian Medical Association
Verified
Journal Article
Open access
PDF file
ESElvando Tunggul Mauliate Simatupang
Elvando Tunggul Mauliate Simatupang
ASArya Marganda Simanjuntak
Arya Marganda Simanjuntak
IYIndra Yovi
Indra Yovi
RSRohani Lasmaria Simbolon
Rohani Lasmaria Simbolon
SMSri Melati Munir
Sri Melati Munir
DWDewi Wijaya
Dewi Wijaya
In 2022, there will be 10.6 million cases of tuberculosis, which is a serious problem worldwide. Thailand's cohort research after the COVID-19 pandemic found a 7-fold risk of tuberculosis infection in COVID-19 patients, pointing to a probable rise in TB cases. In order to completely eradicate TB, care must be given to patients both before and after infection, guaranteeing public health against TB infection.1,2